作者: Janet E. Dancey , Philippe L. Bedard , Nicole Onetto , Thomas J. Hudson
DOI: 10.1016/J.CELL.2012.01.014
关键词: Biology 、 Cancer 、 Conceptual framework 、 MEDLINE 、 Clinical trial 、 Knowledge management 、 Precision medicine 、 Repertoire 、 Personalized medicine 、 Cancer treatment
摘要: Personalized cancer medicine is based on increased knowledge of the mutation repertoire and availability agents that target altered genes or pathways. Given advances in genetics, technology, therapeutics development, timing right to develop a clinical trial research framework move future decisions from heuristic evidence-based decisions. Although challenges integrating genomic testing into treatment decision making are wide-ranging complex, there scientific ethical imperative realize benefits personalized medicine, given overwhelming burden unprecedented opportunities for advancements outcomes patients.